The serotonergic agent m-chlorophenylpiperazine induces migraine attacks: A controlled study

Neurology. 2000 Jul 12;55(1):136-9. doi: 10.1212/wnl.55.1.136.

Abstract

In a double-blind study versus placebo, the serotonergic agent m-chlorophenylpiperazine (mCPP) was administered to 20 healthy control subjects and 19 migraineurs to investigate the ability of mCPP (0.5 mg/kg) to induce typical migraine attacks. In the following 24 hours there were more migraines after mCPP than after placebo in both groups. These findings are consistent with involvement of 5HT2B,2C,1A receptor subtypes in the pathophysiology of migraine.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Migraine Disorders / chemically induced*
  • Migraine Disorders / physiopathology
  • Pain Measurement
  • Piperazines / administration & dosage
  • Piperazines / adverse effects*
  • Piperazines / blood
  • Serotonin Receptor Agonists / administration & dosage
  • Serotonin Receptor Agonists / adverse effects*
  • Serotonin Receptor Agonists / blood

Substances

  • Piperazines
  • Serotonin Receptor Agonists
  • 1-(3-chlorophenyl)piperazine